Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting about 25% of world population, while there are still no approved targeted therapies. Although platensimycin (PTM) was first discovered to be a broad-spectrum antibiotic, it was also effective against type II diabetes in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Meng, Cao, Danfeng, Wang, Zhe, Duan, Yanwen, Huang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773228/
https://www.ncbi.nlm.nih.gov/pubmed/35052685
http://dx.doi.org/10.3390/biomedicines10010005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773228/
https://www.ncbi.nlm.nih.gov/pubmed/35052685
http://dx.doi.org/10.3390/biomedicines10010005

Ejemplares similares